Activity of sorafenib against desmoid tumor/deep fibromatosis Academic Article uri icon

Overview

MeSH Major

  • Benzenesulfonates
  • Fibromatosis, Aggressive
  • Protein Kinase Inhibitors
  • Pyridines

abstract

  • Sorafenib is active against desmoid tumors. A prospective, randomized clinical trial of sorafenib against other active agents is warranted. Loss of MRI T2 signal may be a useful surrogate for defining responses, but requires validation by examination of tumor pathology.

publication date

  • June 15, 2011

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed Central ID

  • PMC3152981

Digital Object Identifier (DOI)

  • 10.1158/1078-0432.CCR-10-3322

PubMed ID

  • 21447727

Additional Document Info

start page

  • 4082

end page

  • 90

volume

  • 17

number

  • 12